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Background: Although Taxane is widely used for various types of 
cancer for lung cancer treatment, it is used for no more than ﬁve years. 
Thus, there is not enough data on survival beneﬁt of this new agent. 
In order to investigate the impact of Taxane in the survival of patients 
with NSCLC, a multi-centre retrospective investigation was conducted 
between 1st January 1995 and 31st December 2006. 
Methods: Two groups of patients were included: Group A consisted 
of 403 patients (338 males and 45 females), median 61,00 ± 0.41 
years, treated with Docetaxel (D) in a dose of 100mg/m2 in a two-hour 
infusion, combined with Carboplatin (C) in a dose of AUC = 5.5 in a 
four-week interval up to 8 cycles. Group A consisted of 288 patients 
(266 males and 22 females), median 62 ± 0.47 years, treated with a 
variety of chemotherapeutic agents including Carboplatin in the same 
dose as in group A, following the same number and cycle interval. No 
statistically signiﬁcant differences were observed in age, histological 
type, performance status and TNM staging between the two investi-
gated groups. 
Results: The table shows the median survival in each group of patients. 
Kaplan Mayer method was used to estimate survival curves and log 
rank correlation to check for statistical difference between the two 
groups. 
 N Survival (in days) P
  Median ± SEM (95% CI) (log rank)
Group A 403 356 ±19.3 (318 - 393.9)  
Group B (all cases) 288 250 ± 15.3 (287.4 - 342.5)  
Group A 197 411 ± 40.5 (331.6 - 490) 0.047
Group B (stage IIIb) 173 286 ± 31 (224.6 - 347)  
Group A 206 299 ± 20 (259 - 338.7) 0.007
Group B (stage IV) 115 203 ±26 (151 - 254.7)
A statistical signiﬁcant increase in patients’ survival of group A was 
observed compared to group B, especially in patients of stage IV. More-
over, an increase in survival of group A was observed in stage IIIB, but 
at the limits of signiﬁcancy. 
Conclusion: It seems that D administration increases survival in 
patients with NSCLC especially in stage IV. On the other hand, in stage 
IIIb the survival beneﬁt is at the limits of signiﬁcancy.
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Objective: Recent trials have shown signiﬁcant survival beneﬁt from 
adjuvant chemotherapy after resection of NSCLC. Whether elderly 
patients tolerate platinum-based adjuvant chemotherapy and derive 
the same survival advantage is unknown. This retrospective study 
evaluated the inﬂuence of age on survival, chemotherapy delivery and 
toxicity. 
Methods: Pretreatment characteristics, follow up data and survival 
beneﬁt from treatment were collected. Chemotherapy delivery, toxicity 
1-year survival and disease control rate (DCR) were compared for 99 
treated patients. 
Results: There were 99 elderly patients who were over 75 years. 
Overall DCR was 83%, that for monotherapy, two-drug and three-drug 
were 66.7%, 81% and 91%, respectively. 1-year survival rate was 
38%,15%,25% and 66%, respectively. The toxicity was tolerable. 
Conclusions: chemotherapy improves overall survival in patients aged 
over 75 years with acceptable toxicity. chemotherapy should not be 
withheld from elderly patients.
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Objectives: To investigate the expression of extracellular matrix in 
neo-adjuvant chemotherapy and control group, and its relationship with 
clinical signiﬁcance in non-small cell lung cancer. 
Methods: Expression of extracellular matrix in lung cancer tissues 
was detected in 73 patients by using immunohistochemistry Envision 
method. 
Results: The median survival of 14 patients with low expression of 
ﬁbronetin was 67month, 57 patients with positive expression was 
38month. A signiﬁcant difference existed between the two groups 
(P=0.048). The high expression of laminin in neo-adjuvant chemother-
apy group were negatively related to clinical response.When analyzed 
only patients randomized to neo-ajuvant chemotherapy using cox step-
wise regression analysis, the TNM stage is the only prognosis factor to 
survival. 
Conclusion: Overexpression of some extracellular matrix may be 
involved in the negative chemoresponse rate. The survival time of 
ﬁbronectin and laminin negative patients may be longer than positive 
patients.
P2-327 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
First-line chemotherapy of vinorelbine/cisplatin (NP) combined 
with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-
cell lung cancer (NSCLC) 
Zhou, Songwen; Zhou, Caicun; Xu, Jianfang; Lv, Meijun 
Shanghai Pulmonary Hospital, Shanghai, China
Objective: To investigate efﬁcacy and safety of ﬁrst-line chemo-
therapy of vinorelbine/cisplatin (NP) combined with cyclooxygenase-2 
inhibitor celecoxib in advanced non-small-cell lung cancer (NSCLC) 
patients. 
Methods: 65 NSCLC patients were randomly assigned to Arm A or B. 
In the arm A, 32 patients were treated with vinorelbine 25mg/m2 iv on 
days 1 and 8, cisplatin 75mg/m2 iv on day 1 and celecoxib 400mg bid 
po on days 1 to 12, repeated every 21 days. In the arm B, 33 cases were 
treated with NP regimen alone. 
Results: Compared with arm B, the response rate in arm A was 
35.5% vs 26.7%(P=0.457), disease control rate was 87.1% vs 
66.7%(P=0.058), one-year survival rate was 58.1% vs 36.7%(P=0.094) 
and median survival time was 12 months vs 9.2 months 
(P=0.062)respectively. Subgroup analysis showed that in the 36 adeno-
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carcinoma patients, one-year survival rate and median survival time 
were signiﬁcantly higher in arm A than in arm B (64.7% vs 26.3%, 
P=0.021) and (12.5 months vs 8.7months, P=0.033) respectively. Nau-
sea/vomiting occurred more frequently in arm A than in arm B(67.74% 
vs 40.0%, P=0.030). There was no statistically difference between two 
groups in the other side-effects. 
Conclusions: The regimen of NP combined with COX-2 inhibitor 
celecoxib was effective and tolerable as the ﬁrst-line chemotherapy in 
advanced NSCLC.In the subgroup of adenocarcinoma, The one-year 
survival rate and median survival time of those treated with NP com-
bined with celecoxib were signiﬁcantly higher.
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Purpose: Mutations in epidermal growth factor receptor (EGFR) are 
considered as a strong predictive marker for the response to EGFR ty-
rosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) 
patients. This study by Korean Cancer Study Group (KCSG) was con-
ducted to determine the clinical implications of EGFR gene mutation, 
increased gene copy number and protein over-expression in Korean 
patients with advanced NSCLC who were treated with erlotinib. 
Patients and Methods: A total of 120 patients received erlotinib 
(TARCEVA®) at a dose of 150mg daily between January 2005 and 
February 2006. Ninety-two tissue samples obtained from these patients 
were analyzed for EGFR mutation (exon 18-21) and K-ras mutation, 
88 samples for EGFR gene ampliﬁcation by real-time PCR, and 77 
samples for EGFR protein expression by means of immunohistochemi-
cal staining. 
Results: Twenty-four out of 92 patients (26.1%) had EGFR muta-
tions in exon 18, 19, and 21, most commonly in exon 19 (75% 18/24). 
A higher frequency was noted in female patients (40.0% vs 17.5%, 
p=0.017). Higher rate of response to erlotinib was noted in patients 
with EGFR mutations compared to wild type (58.3% vs 16.2%, 
p<0.0001). With 14.5 month of median follow-up duration, time to 
progression (TTP) and overall survival (OS) were signiﬁcantly longer 
in patients with mutations than those without mutations (p=0.003, 
p=0.042). Increased EGFR gene copy number was found in 40.9% 
(36/88) of the PCR samples. Patients with increased gene copy num-
ber achieved higher rate of response to erlotinib (38.9% vs 17.3%, 
p=0.023). Also patients with high gene copy number showed longer 
TTP (p<0.0001) and OS (p=0.022). Forty-six out of 75 patients (72%) 
positively expressed the EGFR protein, although there was no relation-
ship between the EGFR expression and the response to erlotinib, TTP 
or OS. 
Conclusion: Our ﬁndings indicate that both EGFR mutation and EGFR 
gene ampliﬁcation were shown to be important predictive markers not 
only for achieving clinical response to erlotinib but also for the prolon-
gation of overall survival in Korean patients with advanced NSCLC.
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Background: Erlotinib is the ﬁrst orally available selective EGFR 
tyrosine-kinase inhibitor that improves survival in 2nd and 3rd line 
therapy for NSCLC. More than 50% of newly patients diagnosed with 
NSCLC are over the age of 65 and 30-40% over the age of 70. Several 
studies suggested an increased risk of toxicity in patients >70 years 
when treated with chemotherapy due to reduced organ function and the 
presence of comorbidities. Single agent treatment is considered an op-
tion of choice in this subset of patients. We have evaluated the efﬁcacy 
of Erlotinib in elderly patients (≥70 yrs) with advanced or metastatic 
NSCLC.
Methods: The TargeT trial was an open-label multicenter study carried 
out in 103 Spanish institutions. Elderly patients (70 and older) included 
in this trial were eligible for this analysis. All patients had conﬁrmed 
advanced or metastatic NSCLC, PS 0-2 and adequate organ function, 
and had received prior chemotherapy or not. Patients were treated with 
Erlotinib 150 mg/day po until disease progression or withdrawal.
Results: From April 2004 to March 2006, 1.796 patients (p) were 
included in the TargeT trial. By the time of this analysis, data from 570 
p (≥ 70 years old) were available. Demographics: males 73.9%; median 
age: 75 yrs. [range 70-95]; stage IV: 76.1%; PS 0-1: 72.1%; histology: 
adenocarcinoma 51.4%, SCC 26.7%, LCC 15.6%, other 6.3%. Current/
ever smokers 73.0%; 1st/2nd/3rd or further: 46.7%/36.3%/17.0%. 
In the evaluable population for response (302 p) 23.8% reached partial 
response and 2 p complete response (0.7%). Of interest, both complete 
responses were detected in p treated with Erlotinib in the ﬁrst line set-
ting. Control disease rate was 67.6%. In the univariate analysis RR was 
signiﬁcantly higher among women (51.5%; p<0.0001), non-smokers 
(51.0%; p<0.0001), adenocarcinomas (31.8%; p=0.003) and those treat-
ed with Erlotinib in the ﬁrst line setting (30.7% vs. 18.4%; p=0.01). 
In the ITT population, median time to progression (TTP) was 5.4 
months [95% CI 4.5-6.5] and median survival was 6.2 months [95% 
CI 5.2-7.1]. In the univariate analysis, predictive factors for longer 
